Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Dr. Scott Pollack – IDO Inhibitors and their Pharmacological Effects

In conjunction with his presentation at the London Excel at ELRIG Drug Discovery 2018, Dr. Scott Pollack, Associate Director of Biophysics and Enzymology at Sygnature Discovery, was asked:

“What are IDO inhibitors and how do you assess their pharmacological effects?”

Latest News

View All

Sygnature Discovery shortlisted for BioNow Company of…

Sygnature upgrades western blotting capability with Jess…

Dr Paul Overton becomes Chief Commercial Officer…

£3M investment to expand high-throughput screening and…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.